Akademik Veri Yönetim Sistemi
Dialysis and Transplantation, cilt.38, sa.6, ss.203-209, 2009 (SCI-Expanded)
OBJECTIVE: Anemia is a major clinical problem in patients receiving dialysis therapy and has a substantial impact on morbidity and mortality. Iron metabolism is impaired in chronic kidney disease. Hepcidin functions as a key regulator of iron metabolism. The aims of this study were to compare the serum pro-hepcidin levels in patients with either peritoneal dialysis (PD) or hemodialysis (HD) and control subjects and to evaluate pro-hepcidin and C-reactive protein (CRP), iron parameters, and hemoglobin levels in PD and HD patients with normal serum CRP levels. METHODS: We studied 85 PD patients, 43 HD patients on regular follow-up, and a control group that was comprised of 41 volunteers in this cross-sectional study. Pro-hepcidin and CRP were studied using commercially available kits. Iron status was assessed by measuring serum iron, transferrin saturation, and ferritin. RESULTS: Pro-hepcidin levels were significantly higher in dialysis patients than the control subjects (p < .001). Hemodialysis patients had higher pro-hepcidin levels than PD patients; but, this difference was not statistically significant (393.4 ± 157.3 versus 361.3 ± 40.1, p = .19). There were no correlations between pro-hepcidin levels and CRP, and hemoglobin level and iron parameters in PD and HD patients. CONCLUSION: The present results suggest that dialysis therapy is associated with elevated pro-hepcidin levels and not directly related to CRP, indices of iron metabolism, or hemoglobin levels. Peritoneal dialysis patients have relatively lower pro-hepcidin levels than HD patients, but larger-scale studies are needed to confirm the possibility of impact on various dialytic modalities.